Horne, G. A. http://orcid.org/0000-0001-9741-7352
Stobo, J.
Kelly, C.
Mukhopadhyay, A.
Latif, A. L.
Dixon-Hughes, J.
McMahon, L.
Cony-Makhoul, P.
Byrne, J. http://orcid.org/0000-0002-9381-1851
Smith, G.
Koschmieder, S. http://orcid.org/0000-0002-1011-8171
BrÜmmendorf, T. H.
Schafhausen, P.
Gallipoli, P. http://orcid.org/0000-0001-7254-2253
Thomson, F.
Cong, W.
Clark, R. E.
Milojkovic, D.
Helgason, G. V.
Foroni, L.
Nicolini, F. E.
Holyoake, T. L.
Copland, M. http://orcid.org/0000-0002-7655-016X
Article History
Received: 8 August 2019
Revised: 23 December 2019
Accepted: 24 December 2019
First Online: 10 January 2020
Compliance with ethical standards
:
: ALL: honoraria (Kite a Gilead Company), speakers bureau (Kite a Gilead Company) and consulting or advisory role (Jazz Pharmaceuticals). JB: honoraria (Novartis, Pfizer) and speakers bureau (Novartis, Pfizer, Jazz Pharmaceuticals, Alexion). GS: research funding (Novartis, Pfizer, Ariad). SK: honoraria (Novartis, BMS, Pfizer, Incyte, Roche, AOP Pharma, Janssen, Bayer) and consulting or advisory role (Pfizer, Incyte, Novartis, AOP Pharma, BMS, CTI, Roche, Bayer). SK: research funding (Novartis, BMS, Janssen). THB: consulting or advisory role (Novartis, Pfizer, Janssen, Merck, Takeda) and research funding (Novartis, Pfizer). PS: honoraria (BMS, Novartis, Alexion, MerckSerono, Pfizer, MSD, Roche, Gilead) and consulting or advisory role (BMS, Novartis, Merck Serono, Alexion, Pfizer). PG: honoraria (BMS). FT: consulting or advisory role (bionomics) and research funding (Roche, Lilly, AstraZeneca). REC: honoraria (Novartis, Pfizer, BMS), consulting or advisory role (Novartis, Pfizer, Jazz Pharmaceuticals, Abbvie) and research funding (Novarits, BMS). DM: consultancy and honoraria (ARIAD, Bristol-Myers Squibb, Novartis, Pfizer, Incyte) and speakers bureau (Incyte). FEN: consulting or advisory role (Incyte, Sun Pharma Ltd) and speakers bureau (Incyte, BMS, Novartis). TLH (sadly passed away): research funding (Novartis, BMS), advisory board member (Novartis, Incyte), and honoraria (BMS, Novartis, Incyte). MC: research funding (Novartis, BMS, Cyclacel, Incyte), advisory board member (BMS, Novartis, Incyte, Pfizer), and honoraria (Astellas, BMS, Novartis, Incyte, Pfizer, Takeda, Celgene). The other authors have no competing financial interests to disclose.
Free to read: This content has been made available to all.